CJC-1295 + Ipamorelin – 5mg + 5mg no dac

CJC-1295 + Ipamorelin – 5mg + 5mg no dac
CJC-1295 and Ipamorelin are synthetic peptides classified as growth hormone secretagogues, combined for their complementary pharmacokinetic profiles. CJC-1295 (Mod GRF 1-29) is a 29-amino acid tetra-substituted analog of GHRH, incorporating a Drug Affinity Complex (DAC) that covalently binds to serum albumin, extending its half-life from approximately 10 minutes to an estimated 5.8–8.1 days. CJC-1295 stimulates growth hormone release by binding GHRH receptors on anterior pituitary somatotrophs, activating G-proteins and downstream cAMP signaling cascades. Clinical data reported a 7.5-fold increase in growth hormone pulsatility and potential increases in GH concentrations by 2- to 10-fold. Ipamorelin (NNC 26-0161) is a synthetic pentapeptide considered one of the most selective growth hormone secretagogues, acting via molecular mimicry of ghrelin at the GHS-R1a receptor without affecting secretion of other pituitary hormones including prolactin, FSH, LH, TSH, or ACTH. Ipamorelin exhibits a shorter half-life of approximately 2 hours, providing rapid onset of action. When combined, Ipamorelin initiates earlier GH release while CJC-1295 extends the duration, producing a synergistic temporal profile that may positively influence lean body mass, insulin utilization, and overall metabolic function.